Not available
Quote | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Last: | $3.90 |
---|---|
Change Percent: | -1.53% |
Open: | $3.98 |
Close: | $3.90 |
High: | $3.98 |
Low: | $3.86 |
Volume: | 729,701 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Arbutus Biopharma Corporation (NASDAQ:ABUS)
2024-07-23 10:38:53 ET More on the markets Playing Real-Life Monopoly With Blackstone Nasdaq, S&P, Dow are muted as investors brace for key tech earnings Barclays ups S&P year-end target to 5,600, stating the recent selloff looks contained S&P...
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Message Board Posts | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Subject | By | Source | When |
---|---|---|---|
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/30/2023 11:03:50 PM |
Arbutus Biopharma Corporation (Nasdaq: $ABUS), a clinical-stage biopharmaceutical | mick | investorshub | 04/18/2023 8:07:45 PM |
With a median price-to-sales (or "P/S") ratio of | mick | investorshub | 04/18/2023 8:06:48 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/15/2023 6:42:52 PM |
rare form / https://investorshub.advfn.com/Arbutus-Biopharma-Corporation-17838#: | mick | investorshub | 04/15/2023 6:42:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...